Traumatic Brain Injury - Bronson Healthcare
A randomized, double-blind, placebo-controlled Phase III study to investigate the efficacy and safety of progesterone in patients with severe traumatic brain injury.

Sponsored by BHR Pharma, LLC. The SyNAPSe trial will study if giving intravenous (i.v.) progesterone within 8 hours of the injury for a total of 120 hours to severe traumatic brain injury patients improves their recovery. Identifier:

  • NCT01143064

Principal Investigator:

Study Status:

  • Enrolling

Study Contact


Related Information

Donate Icon

Help Bronson support our community with a monetary donation.

Donate Today

View Additional Section Content